CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias

Neurology

Volumn 75, Issue 20, 2010, Pages 1760-1761

  Ballard, Clive G ^a   Jones, Emma L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE TRANSPORTER; OLIGOMER;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOPRECIPITATION; NEUROIMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 78649986066     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181fd6393     Document Type: Editorial

References (10)

1. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FPCIT SPECT in dementia with Lewy bodies: A phase III, multicentre study. Lancet Neurol 2007;6:305-313.
2. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first crosssectional study in patients with neurodegeneration. Exp Neurol 2008;213:315-325.
3. El-Agnaf OM, Salem SA, Paleologou KE, et al. α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003;17:1945-1947.
4. Ballard C, Jones EL, Londos E, Minthon L, Francis P, Aarsland D. α-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. Int Psychogeriatr 2010;22:321-327.
5. Öhrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid α-synuclein in neurodegenerative disorders: A marker of synapse loss? Neurosci Lett 2009;450:332-335.
6. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006;5:228 -234. Erratum in: Lancet Neurol 2006;5:293.
7. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766-1772.
8. Borghi R, Marchese R, Negro A, et al. Full length alphasynuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000;287:65-67.
9. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006;281:29739-29752.
10. Murray IV, Giasson BI, Quinn SM, et al. Role of alphasynuclein carboxy-terminus on fibril formation in vitro. Biochemistry 2003;42:8530-8540.